{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.27","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9766","paramType":"Hazard Ratio (HR)","paramValue":"1.00","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"12.3","value":"10.1"},{"groupId":"OG001","lowerLimit":"8.5","upperLimit":"14.4","value":"10.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"247"}],"units":"Participants"}],"description":"OS was defined as the time from the date of study randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 44.7 months","title":"Part 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}